Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liverfibrosis: A pathological analysis

Hepatology

Volumn 49, Issue 3, 2009, Pages 851-859

  Paradis, Valérie ^a,b   Zalisnski, Stéphane ^a,e   Chelbi, Emna ^a   Guedj, Nathalie ^a,b   Degos, Françoise ^c   Vilgrain, Valérie ^d   Bedossa, Pierre ^a,b   Belghiti, Jacques ^a,e  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c AP HP   (France)

^d Service de Radiologie   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RISK; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR VOLUME; CHRONIC DISEASE; COMPARATIVE STUDY; LIVER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 63349085247     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22734     Document Type: Article

References (40)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127:S5-S16.
3. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. HEPATOLOGY 2002;36:1349-1354.
4. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
5. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999;19:221-229.
6. Angulo P. Non alcoholic fatty liver diseases. N Engl J Med 2002;346: 1221-1231.
7. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. HEPATOLOGY 1990;11:74-80.
8. Adams LA, Lymp JF, Sauver JS, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-121.
9. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. HEPATOLOGY 2006;43:S99-S112.
10. Hui JM, Kench JG, Chitturi S, Suda A, Farrell GC, Byth K, et al. Longterm outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. HEPATOLOGY 2003;38:420-427.
11. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. HEPATOLOGY 1999;29:664-669.
12. Poonwala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. HEPATOLOGY 2000;32:689-692.
13. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123: 134-140.
14. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002;37:154-160.
15. Hai S, Kubo S, Shuto T, Tanaka H, Takemura S, Yamamoto T, et al. Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases. Surg Today 2006;36:390-394.
16. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. HEPATOLOGY 2002;35:1485-1493.
17. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126: 460-468.
18. Nair S, Mason A, Eason J, Loss G, Perillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? HEPATOLOGY 2002; 36:150-155.
19. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
20. Zen Y, Katanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. Hepatocellular carcinoma arising in non-alcoholic steato-hepatitis. Pathol Int 2008;51:127-131.
21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. HEPATOLOGY 2005,41:1313-1321.
23. Bedossa P, Poynard T, and the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. HEPATOLOGY 1996;24:298-293.
24. Paradis V, Benzekri A, DargèreD, Bièche I, Laurendeau I, Vilgrain V, et al. Telangiectatic focal nodular hyperplasia: A variant of hepatocellular adenoma. Gastroenterology 2004;126:1323-1329.
25. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353: 1253-1125.
26. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. HEPATOLOGY 2006;44:865-873.
27. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000;92:1096-1099.
28. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127:S97-S103.
29. Regimbeau JM, Colombat M, Mognol P, Durand D, Abdalla E, Degott C, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69-S73.
30. Lam CM, Chan AOO, Ho P, Ng IOL, Lo CM, Liu CL, et al. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients: Implications for screening. Aliment Pharmacol Ther 2004;19:771-777.
31. Wang Y, Cui F, Lv Y, Li C, Xu X, Deng C, et al. HBsAg and HBx knocked into p21 locus causes hepatocellular carcinoma in mice. HEPATOLOGY 2004;39:318-324.
32. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21.
33. Moller H, Mellemgaard A, Lindvig K, Olsen J. Obesity and cancer risk: A Danish record-linkage study. Eur J Cancer 1994;30A:344-350.
34. Wideroff L, Gridley G, Mellelkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-1365.
35. Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X, et al. Oxidative stress and oval cell accumulation in mice and humans in alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003,163:1301-1311.
36. Kim H, Park C, Han K-H, Choi J, Kim YB, Kim JK, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004;40:298-304.
37. Hu W, Feng Z, Eveleugh J, Iyer G, Pan J, Amin S, et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002;23:1781-1789.
38. Paradis V, Champault A, Ronot M, Deschamps L, Valla DC, Vidaud D, et al. Telangiectatic adenomas: An entity associated with increased body mass index and inflammation. HEPATOLOGY 2007;46:140-146.
39. Pawlick TM, Delman KA, Vauthey J-N, Nagorney DM, Oi-Lin Ng I, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-1092.
40. Kojiro M. Pathology of Hepatocellular Carcinoma. Oxford, England: Blackwell Publishing; 2006:82.